Jeuveau (Prabotulinum Toxin Type A) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Jeuveau. Always confirm against the full prescribing information.
100 interactions
Baclofen
The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Baclofen.
Level 1 evidence
Beclomethasone dipropionate
The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Beclomethasone dipropionate.
Level 2 evidence
Betamethasone
The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Betamethasone.
Level 2 evidence
Budesonide
The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Budesonide.
Level 2 evidence
Chloroquine
The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Chloroquine.
Level 1 evidence
Ciclesonide
The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Ciclesonide.
Level 2 evidence
Clindamycin
The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with DaxibotulinumtoxinA.
Level 1 evidence
Clobetasol propionate
The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Clobetasol propionate.
Level 2 evidence
Colistimethate
The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Colistimethate.
Level 1 evidence
Corticotropin
The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Corticotropin.
Level 2 evidence
Cortisone acetate
The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Cortisone acetate.
Level 2 evidence
Cyclosporine
The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Cyclosporine.
Jeuveau (Prabotulinum Toxin Type A) has 173 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Jeuveau (Prabotulinum Toxin Type A) has 0 major, 67 moderate, and 106 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Jeuveau. Always confirm against the full prescribing information.